Imiquimod Treatment for Conjunctival Melanoma In Situ or Ocular Surface Squamous Neoplasia
Study results suggest that, although definitive safety and efficacy cannot be determined across only 5 cases, compounded imiquimod 5% ointment may be a safe and effective approach to manage diffuse conjunctival MIS or OSSN. Longer-term follow-up with larger number of cases is warranted.
Authors
- Randy C. Bowen (ORCID: https://orcid.org/0000-0002-5836-1541)
- Pedram Gerami (ORCID: https://orcid.org/0000-0002-6194-1037)
- Paul J. Bryar (ORCID: https://orcid.org/0000-0001-8494-3089)
Institutions
- Northwestern University (US)
Publication Details
- Journal
- JAMA Ophthalmology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1001/jamaophthalmol.2025.4669
- Citations
- 1
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71